JP2006514683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514683A5 JP2006514683A5 JP2005501095A JP2005501095A JP2006514683A5 JP 2006514683 A5 JP2006514683 A5 JP 2006514683A5 JP 2005501095 A JP2005501095 A JP 2005501095A JP 2005501095 A JP2005501095 A JP 2005501095A JP 2006514683 A5 JP2006514683 A5 JP 2006514683A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- inflammation
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 206010061218 Inflammation Diseases 0.000 claims 10
- 230000004054 inflammatory process Effects 0.000 claims 10
- 230000003042 antagnostic Effects 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 5
- 210000000936 Intestines Anatomy 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 229920000023 polynucleotide Polymers 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
Claims (22)
- Zven1又はZven2アンタゴニストを含んでなる、哺乳類の腸における炎症を低めるための医薬組成物。
- Zven1又はZven2アンタゴニストを含んでなる、哺乳類の腸における炎症を治療するための医薬組成物。
- 前記アンタゴニストが抗体である請求項１又は２記載の医薬組成物。
- 前記アンタゴニストが、
ａ）抗−イディオタイプ抗体；
ｂ）抗体フラグメント；
ｃ）キメラ抗体；及び
ｄ）ヒト型化抗体、
から選択される請求項１又は２記載の医薬組成物。 - 前記アンタゴニストが受容体であり、そして前記受容体が配列番号２、配列番号29又は配列番号５に示されるようなアミノ酸配列を結合する請求項１又は２記載の医薬組成物。
- 前記受容体が、配列番号27又は配列番号28に記載されるようなアミノ酸配列を含んで成る請求項５記載の医薬組成物。
- 前記アンタゴニストが受容体であり、そして前記受容体の一部が、配列番号２、配列番号29又は配列番号５に示されるようなアミノ酸配列に対して特異的に結合する請求項１又は２記載の医薬組成物。
- 前記炎症が慢性である請求項１又は２記載の医薬組成物。
- 前記炎症が散在性である請求項１又は２記載の医薬組成物。
- 前記炎症が過敏性腸症候群の症状である請求項１又は２記載の医薬組成物。
- 前記炎症が炎症性腸疾患の症状である請求項１又は２記載の医薬組成物。
- 前記炎症性腸疾患が、潰瘍性大腸炎、クローン病又は下痢−傾向過敏性腸症候群である請求項11記載の医薬組成物。
- 配列番号１又は配列番号４のポリヌクレオチド配列、又はそのフラグメントについて生物学的サンプルをスクリーニングすることを含んで成る、前記サンプルにおける炎症性腸疾患を検出するための方法。
- 配列番号２、配列番号29又は配列番号５に示されるようなポリペプチド配列、又はそのフラグメントについて生物学的サンプルをスクリーニングすることを含んで成る、前記サンプルにおける炎症性腸疾患を検出するための方法。
- 配列番号２、配列番号29又は配列番号５に示されるようなポリペプチド配列、又はそのフラグメントについて生物学的サンプルをスクリーニングすることを含んで成る、前記サンプルにおける過敏性腸症候群を検出するための方法。
- 配列番号１又は配列番号４に示されるようなポリヌクレオチド配列、又はそのフラグメントについて生物学的サンプルをスクリーニングすることを含んで成る、前記サンプルにおける炎症性腸疾患を検出するための方法。
- 配列番号２のアミノ酸残基28〜108、配列番号29のアミノ酸残基28〜129又は配列番号５のアミノ酸残基20〜105のアミノ酸配列を含んで成るポリペプチドを含んで成る、哺乳類における炎症性腸疾患を治療するための医薬組成物。
- 前記腸における炎症が低められるか、縮小されるか、又は阻害される請求項17に記載の医薬組成物。
- 配列番号２のアミノ酸残基28〜108、配列番号29のアミノ酸残基28〜129又は配列番号５のアミノ酸残基20〜105のアミノ酸配列を含んで成るポリペプチドを含んで成る、哺乳類における過敏性腸症候群を治療するための医薬組成物。
- 前記腸における炎症が低められるか、縮小されるか、又は阻害される請求項19に記載の医薬組成物。
- 配列番号１又は配列番号５の核酸配列を含んで成るポリヌクレオチド含んで成る、哺乳類における過敏性腸症候群を治療するための医薬組成物。
- 前記腸における炎症が低められるか、縮小されるか、又は阻害される請求項21記載の医薬組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41671902P | 2002-10-07 | 2002-10-07 | |
| US41671802P | 2002-10-07 | 2002-10-07 | |
| US43411602P | 2002-12-16 | 2002-12-16 | |
| US43391802P | 2002-12-16 | 2002-12-16 | |
| US50861403P | 2003-10-03 | 2003-10-03 | |
| US50860303P | 2003-10-03 | 2003-10-03 | |
| PCT/US2003/031562 WO2004032850A2 (en) | 2002-10-07 | 2003-10-07 | Uses of human zven antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514683A JP2006514683A (ja) | 2006-05-11 |
| JP2006514683A5 true JP2006514683A5 (ja) | 2006-11-16 |
Family
ID=32097184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501095A Pending JP2006514683A (ja) | 2002-10-07 | 2003-10-07 | ヒトｚｖｅｎアンタゴニストの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (16) | US7205110B2 (ja) |
| EP (1) | EP1558287A4 (ja) |
| JP (1) | JP2006514683A (ja) |
| AU (2) | AU2003279841A1 (ja) |
| CA (2) | CA2500772A1 (ja) |
| WO (2) | WO2004031367A2 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
| EA005682B1 (ru) | 1998-10-06 | 2005-04-28 | Марк Аарон Эмалфарб | Трансформированные грибы, в частности рода chrysosporium, способные к синтезу гетерологичных полипептидов |
| US6485938B1 (en) | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
| US20040235732A1 (en) * | 2000-11-03 | 2004-11-25 | Qun-Yong Zhou | Method for modulating angiogenesis using prokineticin receptor antagonists |
| US7323334B2 (en) | 2002-10-04 | 2008-01-29 | The Regents Of The University Of California | Screening and therapeutic methods relating to neurogenesis |
| CA2500772A1 (en) | 2002-10-07 | 2004-04-22 | Zymogenetics, Inc. | Uses of human zven antagonists |
| KR101118340B1 (ko) * | 2003-03-12 | 2012-04-12 | 제넨테크, 인크. | 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도 |
| WO2006102112A2 (en) * | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica N.V. | Prokineticin 1 receptor |
| MX2007011848A (es) * | 2005-03-24 | 2008-04-22 | Johnson & Johnson | Antagonistas del receptor de procineticina i. |
| CA2622575A1 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
| CN101495464B (zh) | 2005-12-29 | 2014-03-05 | 詹森药业有限公司 | 激肽原1受体拮抗剂 |
| EP2505651A3 (en) | 2006-12-10 | 2013-01-09 | Dyadic International, Inc. | Isolated fungus with reduced protease activity |
| WO2008121046A1 (en) * | 2007-03-29 | 2008-10-09 | Forskarpatent I Syd Ab | Improvement of gastric emptying in patients suffering from diabetes mellitus |
| US20100286021A1 (en) * | 2007-09-25 | 2010-11-11 | Qun-Yong Zhou | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders |
| US11650213B2 (en) * | 2015-03-30 | 2023-05-16 | Entvantage Diagnostics, Inc. | Devices and assays for diagnosis of viral and bacterial infections |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4756479A (en) * | 1987-04-06 | 1988-07-12 | Lazenby Iii George I | Flush hydrant |
| US5294630A (en) * | 1992-07-07 | 1994-03-15 | Eli Lilly And Company | Treatment of inflammatory bowel disease |
| US6042821A (en) * | 1995-11-21 | 2000-03-28 | Smithkline Beecham Corporation | Method of treating sepsis with chemokines |
| US5891720A (en) | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
| EP1000148A2 (en) | 1997-08-01 | 2000-05-17 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE |
| CA2328895A1 (en) | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7264801B2 (en) | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| US6284725B1 (en) * | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| AU5151100A (en) | 1999-05-19 | 2000-12-05 | Incyte Genomics, Inc. | Extracellular signaling molecules |
| US6485938B1 (en) | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
| EP1230362A2 (en) * | 1999-11-16 | 2002-08-14 | ZymoGenetics, Inc. | Human zven proteins |
| EP1242454A2 (en) * | 1999-12-28 | 2002-09-25 | PHARMACIA & UPJOHN COMPANY | G protein-coupled receptors |
| US7045299B2 (en) | 2000-07-18 | 2006-05-16 | Takeda Pharmaceutical Company Limited | Physiologically active peptide and use thereof |
| WO2002036625A2 (en) * | 2000-11-03 | 2002-05-10 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
| EP1506971A1 (en) * | 2000-11-03 | 2005-02-16 | The Regents of the University of California | Prokineticin polypeptides, related compositions and methods |
| US6671555B2 (en) | 2001-04-27 | 2003-12-30 | Medtronic, Inc. | Closed loop neuromodulation for suppression of epileptic activity |
| AU2002359351A1 (en) | 2001-11-02 | 2003-05-19 | Nuvelo, Inc. | Methods and materials relating to prokineticin-like polypeptides and polynucleotides |
| CA2498264A1 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
| CA2500772A1 (en) * | 2002-10-07 | 2004-04-22 | Zymogenetics, Inc. | Uses of human zven antagonists |
| US7662380B2 (en) | 2003-01-22 | 2010-02-16 | Takeda Pharmaceutical Company Limited | ZAQ ligand-1 antibodies and uses thereof |
| KR101118340B1 (ko) | 2003-03-12 | 2012-04-12 | 제넨테크, 인크. | 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의용도 |
| WO2004087054A2 (en) * | 2003-03-25 | 2004-10-14 | The Regents Of The University Of California | Methods for modulating gastric secretion using prokineticin receptor antagonists. |
| WO2005037870A1 (ja) | 2003-10-22 | 2005-04-28 | Takeda Pharmaceutical Company Limited | 抗体およびその用途 |
| CA2622575A1 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
-
2003
- 2003-10-07 CA CA002500772A patent/CA2500772A1/en not_active Abandoned
- 2003-10-07 US US10/680,755 patent/US7205110B2/en not_active Expired - Fee Related
- 2003-10-07 WO PCT/US2003/031714 patent/WO2004031367A2/en active Application Filing
- 2003-10-07 EP EP03773168A patent/EP1558287A4/en not_active Withdrawn
- 2003-10-07 AU AU2003279841A patent/AU2003279841A1/en not_active Abandoned
- 2003-10-07 CA CA002500962A patent/CA2500962A1/en not_active Abandoned
- 2003-10-07 AU AU2003295343A patent/AU2003295343A1/en not_active Abandoned
- 2003-10-07 WO PCT/US2003/031562 patent/WO2004032850A2/en active Application Filing
- 2003-10-07 US US10/680,800 patent/US7291589B2/en not_active Expired - Fee Related
- 2003-10-07 JP JP2005501095A patent/JP2006514683A/ja active Pending
-
2006
- 2006-10-12 US US11/548,824 patent/US20070065405A1/en not_active Abandoned
- 2006-10-12 US US11/548,805 patent/US7592312B2/en not_active Expired - Fee Related
- 2006-10-12 US US11/548,819 patent/US20070065404A1/en not_active Abandoned
- 2006-10-12 US US11/548,830 patent/US20070078259A1/en not_active Abandoned
- 2006-10-12 US US11/548,814 patent/US20070048258A1/en not_active Abandoned
- 2006-10-12 US US11/548,810 patent/US20070065403A1/en not_active Abandoned
- 2006-10-12 US US11/548,826 patent/US7629445B2/en not_active Expired - Fee Related
- 2006-10-19 US US11/550,982 patent/US7531311B2/en not_active Expired - Fee Related
- 2006-10-19 US US11/550,993 patent/US20070053907A1/en not_active Abandoned
- 2006-10-19 US US11/551,002 patent/US20070053908A1/en not_active Abandoned
- 2006-10-19 US US11/551,008 patent/US20070092912A1/en not_active Abandoned
-
2009
- 2009-06-08 US US12/480,572 patent/US20090312256A1/en not_active Abandoned
- 2009-06-09 US US12/480,993 patent/US20090312257A1/en not_active Abandoned
- 2009-06-12 US US12/484,084 patent/US20090312258A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514683A5 (ja) | ||
| US20240141053A1 (en) | Antibodies against tl1a and uses thereof | |
| JP2012012402A5 (ja) | ||
| RU2701434C2 (ru) | Связывающие белки и способы их применения | |
| US7553489B2 (en) | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | |
| JP2018528773A5 (ja) | ||
| US11161902B2 (en) | Tissue-specific exosomes as biomarkers | |
| Oelzner et al. | Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus–relationship with disease activity and renal involvement | |
| Stoop et al. | Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis | |
| JP2007535912A5 (ja) | ||
| JP2011523550A5 (ja) | ||
| JP2009541204A5 (ja) | ||
| JP2014518883A5 (ja) | ||
| JP6081699B2 (ja) | Ｉｌ−２８ｂの分析方法 | |
| JP2007513633A5 (ja) | ||
| RU2013153592A (ru) | Анти-mif антитела | |
| PT2734549T (pt) | Anticorpo monoclonal contra interleucina-31 canina | |
| EA012464B1 (ru) | Антитело против cd20 и его применение | |
| RU2010151725A (ru) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их | |
| JP2010536886A5 (ja) | ||
| JP2010043063A (ja) | 川崎病の診断及び治療 | |
| JP2013505938A5 (ja) | ||
| JP2004532839A5 (ja) | ||
| JP2016539925A5 (ja) | ||
| JP2007526891A5 (ja) |